Equities

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Actions
  • Price (CHF)134.83
  • Today's Change0.00 / 0.00%
  • Shares traded11.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Neurocrine Biosciences Inc grew revenues 26.76% from 1.49bn to 1.89bn while net income improved 61.62% from 154.50m to 249.70m.
Gross margin98.52%
Net profit margin17.21%
Operating margin25.81%
Return on assets12.09%
Return on equity16.35%
Return on investment14.67%
More ▼

Cash flow in USDView more

In 2023, Neurocrine Biosciences Inc did not generate a significant amount of cash. However, the company earned 389.90m from its operations for a Cash Flow Margin of 20.66%. In addition the company generated 65.30m cash from financing while 467.10m was spent on investing.
Cash flow per share3.98
Price/Cash flow per share30.91
Book value per share26.87
Tangible book value per share26.53
More ▼

Balance sheet in USDView more

Neurocrine Biosciences Inc uses little or no debt in its capital structure.
Current ratio4.37
Quick ratio4.26
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)62.04
EPS (TTM) vs
TTM 1 year ago
99.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.